If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> ONCOLOGY<br /> ISSN 2054-619X Vol 3.2 • November 2015 • emjreviews.com<br /> INSIDE<br /> Review of<br /> ECC 2015<br /> Vienna, Austria<br /> CONTENTS<br /> EDITORIAL BOARD......................................................................................................................................... 4<br /> CONGRESS REVIEW........................................................................................................................................ 12<br /> • Review of the European Cancer Congress 2015, held in Vienna, Austria,<br /> 25th–29th September 2015<br /> INTERVIEWS WITH EMJ ONCOLOGY EDITORIAL BOARD………………….....................……... 30<br /> SYMPOSIUM REVIEWS<br /> • INTELLIGENT APPLICATION OF BREAST CANCER TRIALS DATA IN<br /> THE CLINIC………………………….................................................................................................... 40<br /> • IN<a title="EMJ Oncology 3.2 2015 page 1" href="http://viewer.zmags.com/publication/41054366?page=1"> ONCOLOGY ISSN 2054-619X </a> <a title="EMJ Oncology 3.2 2015 page 2" href="http://viewer.zmags.com/publication/41054366?page=2"> CONTENTS EDITORIAL BOARD.......................</a> <a title="EMJ Oncology 3.2 2015 page 3" href="http://viewer.zmags.com/publication/41054366?page=3"> ONCOLOGY • Adjuvant Radiotherapy in Rectal Canc</a> <a title="EMJ Oncology 3.2 2015 page 4" href="http://viewer.zmags.com/publication/41054366?page=4"> Editorial Board Editor-in-Chief: Dr Ahmad Awad</a> <a title="EMJ Oncology 3.2 2015 page 5" href="http://viewer.zmags.com/publication/41054366?page=5"> Oncology Dr Jeff Lipton, Professor of Medicin</a> <a title="EMJ Oncology 3.2 2015 page 6" href="http://viewer.zmags.com/publication/41054366?page=6"> Precise Efficient Versatile PROVEN AS </a> <a title="EMJ Oncology 3.2 2015 page 7" href="http://viewer.zmags.com/publication/41054366?page=7"> European Medical Journal EMJ Oncology Vol 3.2 N</a> <a title="EMJ Oncology 3.2 2015 page 8" href="http://viewer.zmags.com/publication/41054366?page=8"> Step up with GIOTRIF® (afatinib) to a new level o</a> <a title="EMJ Oncology 3.2 2015 page 9" href="http://viewer.zmags.com/publication/41054366?page=9"> Welcome Hello, and a very warm welcome to the </a> <a title="EMJ Oncology 3.2 2015 page 10" href="http://viewer.zmags.com/publication/41054366?page=10"> ONDELIS*(trabectedin) GOES AROUND THE SARCO</a> <a title="EMJ Oncology 3.2 2015 page 11" href="http://viewer.zmags.com/publication/41054366?page=11"> Foreword </a> <a title="EMJ Oncology 3.2 2015 page 12" href="http://viewer.zmags.com/publication/41054366?page=12"> ECC ANNUAL CONGRESS 2015 MESSE WIEN, VIENNA, AUS</a> <a title="EMJ Oncology 3.2 2015 page 13" href="http://viewer.zmags.com/publication/41054366?page=13"> Welcome to the European Medical Journal revi</a> <a title="EMJ Oncology 3.2 2015 page 14" href="http://viewer.zmags.com/publication/41054366?page=14"> ECC ANNUAL CONGRESS 2015 honoured the progress t</a> <a title="EMJ Oncology 3.2 2015 page 15" href="http://viewer.zmags.com/publication/41054366?page=15"> H IGHLIGHTS Safe Surgery Unavailable</a> <a title="EMJ Oncology 3.2 2015 page 16" href="http://viewer.zmags.com/publication/41054366?page=16"> ECC ANNUAL CONGRESS 2015 19,127 oncology profess</a> <a title="EMJ Oncology 3.2 2015 page 17" href="http://viewer.zmags.com/publication/41054366?page=17"> In the five studies that reported on pr</a> <a title="EMJ Oncology 3.2 2015 page 18" href="http://viewer.zmags.com/publication/41054366?page=18"> ECC ANNUAL CONGRESS 2015 Treatment Delay or Termi</a> <a title="EMJ Oncology 3.2 2015 page 19" href="http://viewer.zmags.com/publication/41054366?page=19"> oncologist, University Hospitals Leuven</a> <a title="EMJ Oncology 3.2 2015 page 20" href="http://viewer.zmags.com/publication/41054366?page=20"> ECC ANNUAL CONGRESS 2015 Fewer significant tr</a> <a title="EMJ Oncology 3.2 2015 page 21" href="http://viewer.zmags.com/publication/41054366?page=21"> added: “The high response rate is exciting i</a> <a title="EMJ Oncology 3.2 2015 page 22" href="http://viewer.zmags.com/publication/41054366?page=22"> ECC ANNUAL CONGRESS 2015 “We fo</a> <a title="EMJ Oncology 3.2 2015 page 23" href="http://viewer.zmags.com/publication/41054366?page=23"> “The increased survival among these patients is r</a> <a title="EMJ Oncology 3.2 2015 page 24" href="http://viewer.zmags.com/publication/41054366?page=24"> ECC ANNUAL CONGRESS 2015 “These</a> <a title="EMJ Oncology 3.2 2015 page 25" href="http://viewer.zmags.com/publication/41054366?page=25"> nivolumab than to everolimus; the objective r</a> <a title="EMJ Oncology 3.2 2015 page 26" href="http://viewer.zmags.com/publication/41054366?page=26"> ECC ANNUAL CONGRESS 2015 for patients with ad</a> <a title="EMJ Oncology 3.2 2015 page 27" href="http://viewer.zmags.com/publication/41054366?page=27"> option for lung and gastrointestinal NETs, an</a> <a title="EMJ Oncology 3.2 2015 page 28" href="http://viewer.zmags.com/publication/41054366?page=28"> ECC ANNUAL CONGRESS 2015 Dr McNally concluded </a> <a title="EMJ Oncology 3.2 2015 page 29" href="http://viewer.zmags.com/publication/41054366?page=29"> EVENTS DIRECTORY 2016 ECCO - the European CanCe</a> <a title="EMJ Oncology 3.2 2015 page 30" href="http://viewer.zmags.com/publication/41054366?page=30"> EDITORIAL BOARD INTERVIEWS Javier Cortés </a> <a title="EMJ Oncology 3.2 2015 page 31" href="http://viewer.zmags.com/publication/41054366?page=31"> Dr Cortés also has a lot of ideas about how to im</a> <a title="EMJ Oncology 3.2 2015 page 32" href="http://viewer.zmags.com/publication/41054366?page=32"> EDITORIAL BOARD INTERVIEWS with Dr Eli Glatstein</a> <a title="EMJ Oncology 3.2 2015 page 33" href="http://viewer.zmags.com/publication/41054366?page=33"> with something for a long time, and so they say t</a> <a title="EMJ Oncology 3.2 2015 page 34" href="http://viewer.zmags.com/publication/41054366?page=34"> EDITORIAL BOARD INTERVIEWS the research point of</a> <a title="EMJ Oncology 3.2 2015 page 35" href="http://viewer.zmags.com/publication/41054366?page=35"> has changed the way we are treating patien</a> <a title="EMJ Oncology 3.2 2015 page 36" href="http://viewer.zmags.com/publication/41054366?page=36"> EDITORIAL BOARD INTERVIEWS everybody can do every</a> <a title="EMJ Oncology 3.2 2015 page 37" href="http://viewer.zmags.com/publication/41054366?page=37"> “Do not use tanning booths – they are probably mo</a> <a title="EMJ Oncology 3.2 2015 page 38" href="http://viewer.zmags.com/publication/41054366?page=38"> EDITORIAL BOARD INTERVIEWS Q: Are there any area</a> <a title="EMJ Oncology 3.2 2015 page 39" href="http://viewer.zmags.com/publication/41054366?page=39"> SUBSCRIBE FREE TO OUR YOUTUBE CHANNEL www.youtube</a> <a title="EMJ Oncology 3.2 2015 page 40" href="http://viewer.zmags.com/publication/41054366?page=40"> INTELLIGENT APPLICATION OF BREAST CANCER TRIALS</a> <a title="EMJ Oncology 3.2 2015 page 41" href="http://viewer.zmags.com/publication/41054366?page=41"> Neoadjuvant and Adjuvant Strategies for HER2-Posi</a> <a title="EMJ Oncology 3.2 2015 page 42" href="http://viewer.zmags.com/publication/41054366?page=42"> Chemotherapy 60% 50% 40% 30% 20% 10% Rate </a> <a title="EMJ Oncology 3.2 2015 page 43" href="http://viewer.zmags.com/publication/41054366?page=43"> HER2+/HR+ postmenopausal limited disease burden </a> <a title="EMJ Oncology 3.2 2015 page 44" href="http://viewer.zmags.com/publication/41054366?page=44"> • For the majority of patients with HER2-positi</a> <a title="EMJ Oncology 3.2 2015 page 45" href="http://viewer.zmags.com/publication/41054366?page=45"> (via prior endocrine therapy) in order for mTOR i</a> <a title="EMJ Oncology 3.2 2015 page 46" href="http://viewer.zmags.com/publication/41054366?page=46"> that cyclin D1 amplification or p16 loss may be go</a> <a title="EMJ Oncology 3.2 2015 page 47" href="http://viewer.zmags.com/publication/41054366?page=47"> Abstract 511. ASCO Annual Meeting, 29 May–2 June </a> <a title="EMJ Oncology 3.2 2015 page 48" href="http://viewer.zmags.com/publication/41054366?page=48"> locally advanced or metastatic breast cancer </a> <a title="EMJ Oncology 3.2 2015 page 49" href="http://viewer.zmags.com/publication/41054366?page=49"> INCORPORATING PARP INHIBITION IN CANCER THERAPY: </a> <a title="EMJ Oncology 3.2 2015 page 50" href="http://viewer.zmags.com/publication/41054366?page=50"> Why Target DNA Repair Mechanisms </a> <a title="EMJ Oncology 3.2 2015 page 51" href="http://viewer.zmags.com/publication/41054366?page=51"> carriers and non-carriers and approximately one- </a> <a title="EMJ Oncology 3.2 2015 page 52" href="http://viewer.zmags.com/publication/41054366?page=52"> placebo as maintenance therapy in patients with B</a> <a title="EMJ Oncology 3.2 2015 page 53" href="http://viewer.zmags.com/publication/41054366?page=53"> Exciting novel options are also emerging and may </a> <a title="EMJ Oncology 3.2 2015 page 54" href="http://viewer.zmags.com/publication/41054366?page=54"> Table 2: Select Phase II/III clinical trials eval</a> <a title="EMJ Oncology 3.2 2015 page 55" href="http://viewer.zmags.com/publication/41054366?page=55"> they would rarely consider BRCA testing for this </a> <a title="EMJ Oncology 3.2 2015 page 56" href="http://viewer.zmags.com/publication/41054366?page=56"> Prof Van Cutsem described results from a recent P</a> <a title="EMJ Oncology 3.2 2015 page 57" href="http://viewer.zmags.com/publication/41054366?page=57"> 29 May-2 June 2015. 18. Kwon JS et al. Expanding </a> <a title="EMJ Oncology 3.2 2015 page 58" href="http://viewer.zmags.com/publication/41054366?page=58"> 47. National Institutes of Health. A study evalua</a> <a title="EMJ Oncology 3.2 2015 page 59" href="http://viewer.zmags.com/publication/41054366?page=59"> CABOZANTINIB VERSUS EVEROLIMUS IN PATIENTS WITH</a> <a title="EMJ Oncology 3.2 2015 page 60" href="http://viewer.zmags.com/publication/41054366?page=60"> Patients with advanced or metastatic clear cell R</a> <a title="EMJ Oncology 3.2 2015 page 61" href="http://viewer.zmags.com/publication/41054366?page=61"> Progression-free survival (%) 100 90 80 70 60 50</a> <a title="EMJ Oncology 3.2 2015 page 62" href="http://viewer.zmags.com/publication/41054366?page=62"> Overall survival (%) 100 90 80 70 60 50 40 30 20</a> <a title="EMJ Oncology 3.2 2015 page 63" href="http://viewer.zmags.com/publication/41054366?page=63"> In conclusion, METEOR met its primary endpoint, w</a> <a title="EMJ Oncology 3.2 2015 page 64" href="http://viewer.zmags.com/publication/41054366?page=64"> ABSTRACT REVIEWS PERSPECTIVES IN MANAGEME</a> <a title="EMJ Oncology 3.2 2015 page 65" href="http://viewer.zmags.com/publication/41054366?page=65"> ECC 4. Sequist LV et al. Phase III study of afati</a> <a title="EMJ Oncology 3.2 2015 page 66" href="http://viewer.zmags.com/publication/41054366?page=66"> ABSTRACT REVIEWS patients with brain/leptomening</a> <a title="EMJ Oncology 3.2 2015 page 67" href="http://viewer.zmags.com/publication/41054366?page=67"> ECC prognosis of CLL, patients are likely to ben</a> <a title="EMJ Oncology 3.2 2015 page 68" href="http://viewer.zmags.com/publication/41054366?page=68"> ABSTRACT REVIEWS 6. Byrd JC et al. Ibrutinib ver</a> <a title="EMJ Oncology 3.2 2015 page 69" href="http://viewer.zmags.com/publication/41054366?page=69"> ECC Mucin MUC1 expression is altered, mainl</a> <a title="EMJ Oncology 3.2 2015 page 70" href="http://viewer.zmags.com/publication/41054366?page=70"> ABSTRACT REVIEWS THE SENTINEL LYMPH NO</a> <a title="EMJ Oncology 3.2 2015 page 71" href="http://viewer.zmags.com/publication/41054366?page=71"> ECC Figure 2: Localisation of axillary draining n</a> <a title="EMJ Oncology 3.2 2015 page 72" href="http://viewer.zmags.com/publication/41054366?page=72"> ABSTRACT REVIEWS ADJUVANT RADIOTHERAPY IN RECTAL</a> <a title="EMJ Oncology 3.2 2015 page 73" href="http://viewer.zmags.com/publication/41054366?page=73"> ECC Lancet Oncol. 2011;12(6):575-82. 4. Sauer </a> <a title="EMJ Oncology 3.2 2015 page 74" href="http://viewer.zmags.com/publication/41054366?page=74"> ABSTRACT REVIEWS across all patients. There are </a> <a title="EMJ Oncology 3.2 2015 page 75" href="http://viewer.zmags.com/publication/41054366?page=75"> ECC more secondary osteosarcomas) and less inten</a> <a title="EMJ Oncology 3.2 2015 page 76" href="http://viewer.zmags.com/publication/41054366?page=76"> ABSTRACT REVIEWS a low concentration of intraven</a> <a title="EMJ Oncology 3.2 2015 page 77" href="http://viewer.zmags.com/publication/41054366?page=77"> ECC proliferative potential of T cells, stable C</a> <a title="EMJ Oncology 3.2 2015 page 78" href="http://viewer.zmags.com/publication/41054366?page=78"> ABSTRACT REVIEWS that of Turcot syndrome and, re</a> <a title="EMJ Oncology 3.2 2015 page 79" href="http://viewer.zmags.com/publication/41054366?page=79"> ECC European consortium ‘care for CMMRD’ (C4CMMRD</a> <a title="EMJ Oncology 3.2 2015 page 80" href="http://viewer.zmags.com/publication/41054366?page=80"> ABSTRACT REVIEWS encouraging, the efficacy of im</a> <a title="EMJ Oncology 3.2 2015 page 81" href="http://viewer.zmags.com/publication/41054366?page=81"> ECC ‘Look while you treat’ as a new concept seem</a> <a title="EMJ Oncology 3.2 2015 page 82" href="http://viewer.zmags.com/publication/41054366?page=82"> ABSTRACT REVIEWS a humanised monoclonal antibody</a> <a title="EMJ Oncology 3.2 2015 page 83" href="http://viewer.zmags.com/publication/41054366?page=83"> ECC Sloan Kettering Cancer Center (New York</a> <a title="EMJ Oncology 3.2 2015 page 84" href="http://viewer.zmags.com/publication/41054366?page=84"> ABSTRACT REVIEWS expression of major histocom</a> <a title="EMJ Oncology 3.2 2015 page 85" href="http://viewer.zmags.com/publication/41054366?page=85"> ECC 15. Golden EB et al. An abscopal response to </a> <a title="EMJ Oncology 3.2 2015 page 86" href="http://viewer.zmags.com/publication/41054366?page=86"> Available Now EMJ Oncology 3.1 2015 I</a> <a title="EMJ Oncology 3.2 2015 page 87" href="http://viewer.zmags.com/publication/41054366?page=87"> CURRENT AND FUTURE DEVELOPMENTS IN THE </a> <a title="EMJ Oncology 3.2 2015 page 88" href="http://viewer.zmags.com/publication/41054366?page=88"> Table 1: Summary of CD30+ diseases. Tissue type</a> <a title="EMJ Oncology 3.2 2015 page 89" href="http://viewer.zmags.com/publication/41054366?page=89"> NOVEL THERAPEUTIC OPTIONS THAT TARGET CD30 One o</a> <a title="EMJ Oncology 3.2 2015 page 90" href="http://viewer.zmags.com/publication/41054366?page=90"> LYSA/FIL/EORTC trial in patients with e</a> <a title="EMJ Oncology 3.2 2015 page 91" href="http://viewer.zmags.com/publication/41054366?page=91"> lymphoma, a B-cell form of non-HL.51 Taken </a> <a title="EMJ Oncology 3.2 2015 page 92" href="http://viewer.zmags.com/publication/41054366?page=92"> 9. Harlin H et al. TCR-independent CD30 si</a> <a title="EMJ Oncology 3.2 2015 page 93" href="http://viewer.zmags.com/publication/41054366?page=93"> Inc. A Phase 3 Trial of Brentuximab Vedotin</a> <a title="EMJ Oncology 3.2 2015 page 94" href="http://viewer.zmags.com/publication/41054366?page=94"> Buyer’s Guide • ABBVIE INC. • ABX-CRO ADVANC</a> <a title="EMJ Oncology 3.2 2015 page 95" href="http://viewer.zmags.com/publication/41054366?page=95"> • MDLINK EUROPE • MEDAC GMBH • MEDGENOME INC. </a> <a title="EMJ Oncology 3.2 2015 page 96" href="http://viewer.zmags.com/publication/41054366?page=96"> SUBSCRIBE TO RECEIVE THE LATEST CATIONS, PUBL</a>